Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

The Lancet Oncology

Volumn 18, Issue 5, 2017, Pages 611-622

  Ascierto, Paolo A ^a   Del Vecchio, Michele ^b   Robert, Caroline ^c   Mackiewicz, Andrzej ^d   Chiarion Sileni, Vanna ^e   Arance, Ana ^f   Lebbé, Céleste ^g   Bastholt, Lars ^h   Hamid, Omid ⁱ   Rutkowski, Piotr ^j   McNeil, Catriona ^k,l   Garbe, Claus ^m   Loquai, Carmen ⁿ   Dreno, Brigitte ^o   Thomas, Luc ^p   Grob, Jean Jacques ^q   Liszkay, Gabriella ^r   Nyakas, Marta ^s   Gutzmer, Ralf ^t   Pikiel, Joanna ^u   Grange, Florent ^v   Hoeller, Christoph ^w   Ferraresi, Virginia ^x   Smylie, Michael ^y   Schadendorf, Dirk ^z   Mortier, Laurent ^aa   Svane, Inge Marie ^ab   Hennicken, Delphine ^ac   Qureshi, Anila ^ac   Maio, Michele ^ad   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g SAINT LOUIS HOSPITAL   (France)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ Angeles Clinic and Research Institute   (United States)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^l MELANOMA INSTITUTE AUSTRALIA   (Australia)

^m UNIVERSITY OF TÜBINGEN   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^o NANTES UNIVERSITY HOSPITAL   (France)

^p CENTRE HOSPITALIER LYON SUD   (France)

^q TIMONE HOSPITAL   (France)

^r NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^s OSLO UNIVERSITY HOSPITAL   (Norway)

^t HANNOVER MEDICAL SCHOOL   (Germany)

^u Wojewodzkie Centrum Oncologii   (Poland)

^v REIMS UNIVERSITY HOSPITAL   (France)

^w MEDICAL UNIVERSITY OF VIENNA   (Austria)

^x Istituti Fisioterapici Ospitalieri Rome   (Italy)

^y CROSS CANCER INSTITUTE   (Canada)

^z UNIVERSITY HOSPITAL ESSEN   (Germany)

^aa LILLE UNIVERSITY HOSPITAL   (France)

^ab UNIVERSITY OF COPENHAGEN   (Denmark)

^ac BRISTOL MYERS SQUIBB   (United States)

^ad UNIVERSITY HOSPITAL OF SIENA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; LIVER ENZYME; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE COLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BICYTOPENIA; CANCER GROWTH; CAUSE OF DEATH; COLITIS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; CYTOMEGALOVIRUS COLITIS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASES; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME BLOOD LEVEL; ERYSIPELAS; ERYTHEMA NODOSUM; FACIAL NERVE PARALYSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL PAIN; GUILLAIN BARRE SYNDROME; HEADACHE; HEART ARREST; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPASEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOPHYSIS DISEASE; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHALAMOPITUITARY DISORDER; HYPOTHALAMUS DISEASE; HYPOTHYROIDISM; INFECTION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LARGE INTESTINE PERFORATION; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER TOXICITY; LOWER ABDOMINAL PAIN; LUNG DISEASE; LYMPHOCYTIC HYPOPHYSITIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MOTOR NEUROPATHY; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCYTOPENIA; PERICARDITIS; PERIPHERAL NEUROPATHY; PERITONITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PROSTATITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; RHEUMATIC POLYMYALGIA; SENSORY NEUROPATHY; SKIN TOXICITY; SMALL INTESTINE OBSTRUCTION; SMALL INTESTINE PERFORATION; THROMBOCYTOPENIA; THYROID CRISIS; THYROIDITIS; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ULCERATIVE COLITIS; UVEITIS; VOMITING; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MELANOMA; MIDDLE AGED; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLITIS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHYSITIS; INTENTION TO TREAT ANALYSIS; MALE; MELANOMA; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85016813132     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30231-0     Document Type: Article

References (24)

1. 1 Hoos, A, Ibrahim, R, Korman, A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37 (2010), 533–546.
2. 2 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
3. 3 Robert, C, Thomas, L, Bondarenko, I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
4. 4 Maio, M, Grob, JJ, Aamdal, S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33 (2015), 1191–1196.
5. 5 Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
6. 6 Wolchok, JD, Neyns, B, Linette, G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
7. 7 Hoos, A, Eggermont, A, Janetzki, S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102 (2010), 1388–1397.
8. 8 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
9. 9 NCI Common Terminology Criteria for Adverse Events (CTCAE) v.3, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. (accessed Nov 23, 2016).
10. 10 Postow, MA, Chesney, J, Pavlick, AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
11. 11 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
12. 12 Weber, JS, D'Angelo, SP, Minor, D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
13. 13 Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
14. 14 EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
15. 15 Osoba, D, Rodrigues, G, Myles, J, Zee, B, Pater, J, Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16 (1998), 139–144.
16. 16 Pickard, AS, Neary, MP, Cella, D, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
17. 17 Brookmeyer, R, Crowley, J, A confidence interval for the median survival time. Biometrics 38 (1982), 29–41.
18. 18 Kalbfleisch, JD, Prentice, RL, The statistical analysis of failure time data, 2002, Wiley-Interscience, Hoboken, NJ.
19. 19 Topalian, SL, Sznol, M, McDermott, DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
20. 20 Ribas, A, Hamid, O, Daud, A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 (2016), 1600–1609.
21. 21 Robert, C, Schachter, J, Long, GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
22. 22 Long, GV, Grob, J-J, Nathan, P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomized trials. Lancet Oncol 17 (2016), 1743–1754.
23. 23 Ascierto, PA, McArthur, GA, Dreno, B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomized, double-blind, phase 3 trial. Lancet Oncol 17 (2016), 1248–1260.
24. 24 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.